T-cell response, antigens, vaccinated own cells attacking virus...

T-cell response, antigens, vaccinated own cells attacking virus etc. have been in the news because COVID vaccines are mainly focussing on these aspects. I believe some major will take a stake in Patrys. The market cap is still only $28 million and we have more than $7 million in cash. A major could value Patrys at say $140 million (10 cents/share) which is still cheap and buy a 10% stake at $14 million which is peanuts for them - and they have a product with blockbuster potential. This investment could be enough to speed up and see us through the trials. After reading Bioshares comments at least we have some hope now - rather than the despair for over 10 years. Good luck to all holders. I think Because of COVID vaccine exposure to our line of treatment, there is some interest from big pharma. Keep the faith.